Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience, Inc. (ANRO) common stock: Vanguard Capital Management reports beneficial ownership of 1,970,108 shares, or 5.02% of the class. It reports sole voting power over 279,355 shares and sole dispositive power over 1,970,108 shares; shared voting and dispositive power are each 0.
The reported amount reflects securities associated with Vanguard Capital Management LLC and named affiliates and business divisions, including fund holdings subject to its dispositive power and client holdings subject to affiliates’ voting and/or dispositive power.
Alto Neuroscience, Inc. President and CFO Nicholas Conrad Smith exercised options for 55,000 common shares on October 2, 2026, at an exercise price of $2.32 per share. Following the transaction, he reported 79,060 directly held common shares and 57,405 options.
The option terms state that 25% of the underlying shares vested on September 8, 2022, with one forty-eighth (1/48th) vesting or to vest in monthly installments thereafter, subject to continuous service through each vesting date.
Alto Neuroscience, Inc. (ANRO) President and CFO Nicholas Conrad Smith exercised options to acquire 134,886 common shares at $2.35 per share on September 29 and 30, 2026, and sold 134,886 shares across those dates. On September 29, he sold 110,830 shares at a weighted average $26.5826 per share. On September 30, he sold 23,170 shares at $25.7786 and 886 shares at $26.87. The transactions were made under a Rule 10b5-1 trading plan adopted June 30, 2026.
Alto Neuroscience, Inc. (ANRO) is the issuer in officer Nicholas Smith’s notice for a proposed sale of 134,886 common shares, with an aggregate market value of $3,596,060.76. The notice lists September 29, 2026, as the approximate sale date and NYSE as the exchange. Smith states that the shares were and will be received upon exercise of stock options over the next three months; acquisition and payment dates are the exercise/sale dates.
Alto Neuroscience, Inc. (ANRO) announced a leadership change effective August 26, 2026. The Board promoted Nicholas C. Smith, previously Chief Financial Officer and Chief Business Officer, to President and Chief Financial Officer. Amit Etkin, M.D., Ph.D. remains Chief Executive Officer and continues to serve as the principal executive officer, while Mr. Smith is the principal financial officer.
Under a new Promotion and Retention Agreement, Mr. Smith is entitled to a cash Retention Payment totaling $6,000,000, with $3,000,000 payable within ten days of August 26, 2026 and $3,000,000 on the twelve-month anniversary of that date, subject to standard deductions and withholdings. If his employment ends for any reason, or for Cause by the company, before the two-year Retention Date, any unpaid portion is forfeited and any paid portion is subject to recoupment within 30 days, except when the company terminates him without Cause or his employment ends due to death or Disability, in which case any unpaid portion will be paid.
Alto Neuroscience, Inc. has an institutional holder group led by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. reporting beneficial ownership of 4,176,711 shares of common stock, equal to 9.99% of the company’s 39,242,104 shares outstanding as of August 7, 2026.
The Master Fund directly holds 1,609,893 shares and 2,898,854 pre-funded warrants exercisable at $0.0001 per share. A “Beneficial Ownership Limitation” caps exercisability so that, as of this report, only 2,566,818 warrant shares are counted toward beneficial ownership, keeping the group at the 9.99% threshold. Perceptive Advisors serves as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Alto Neuroscience, Inc. common stock on an amended Schedule 13G (Amendment No. 2). They report beneficial ownership of 785,000 shares of common stock, representing 2.2% of the class, held through a fund and a managed account advised by Vestal Point Capital.
All 785,000 shares are reported with shared voting and dispositive power and no sole power. The ownership percentage is based on 35,093,940 shares outstanding as of May 8, 2026, as stated in Alto Neuroscience’s Form 10-Q. The filers state that the Schedule 13G should not be construed as an admission of beneficial ownership for Section 13 purposes and confirm they own 5% or less of the class.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Alto Neuroscience, Inc. common stock. They collectively report 2,219,568 shares of Common Stock, including 787,043 shares issuable upon exercise of warrants, representing 6.2% of the class based on 35,093,940 shares outstanding as of May 8, 2026. Voting and dispositive power over these shares is shared, with no sole voting or dispositive power reported. SILV Fund, Ltd. has the right to receive dividends or sale proceeds for more than 5% of the outstanding Common Stock.
Alto Neuroscience, Inc. reported a larger net loss while significantly strengthening its balance sheet for the quarter ended June 30, 2026. Cash and cash equivalents rose to $243.7 million, up from $176.5 million at year-end 2025, driven mainly by a March 2026 private placement of common stock and pre-funded warrants that generated $114.8 million in net proceeds, plus loan conversions.
Operating expenses increased as the pipeline advanced. For the quarter, research and development expense grew to $22.1 million from $13.1 million, and general and administrative expense to $7.0 million from $5.6 million, producing a loss from operations of $29.1 million. Quarterly net loss was $27.6 million versus $17.7 million a year earlier; six‑month net loss was $53.9 million.
Net cash used in operating activities for the first half of 2026 was $46.9 million. Alto ended the period with total assets of $254.1 million, total liabilities of $34.8 million (including a $15.0 million term loan and a $2.5 million fair‑valued convertible grant), and stockholders’ equity of $219.2 million, supporting ongoing clinical programs such as ALTO‑207, ALTO‑300, ALTO‑100, ALTO‑101, and ALTO‑203.
Alto Neuroscience, Inc. reported second quarter 2026 results and pipeline updates focused on its lead program ALTO-207 for treatment-resistant depression. The company expanded ALTO-207 development to include a planned Phase 3 monotherapy trial in addition to an ongoing potentially registrational Phase 2b adjunctive trial, with topline Phase 2b data expected in 2H 2027. Independent data published in Nature Medicine reinforced the dopaminergic mechanism underlying ALTO-207 and showed significant effects on anhedonia. Enrollment continues in Phase 2b trials of ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression, with data expected in 2027.
Alto completed an approximately $100 million registered direct offering in July 2026, resulting in pro forma cash of about $338 million, which the company expects to fund planned operations through 2030. As of June 30, 2026, cash, cash equivalents, and restricted cash were $244.2 million. For the quarter, research and development expenses rose to $22.1 million and general and administrative expenses to $7.0 million, leading to a net loss of $27.6 million compared to $17.7 million a year earlier.